AstraZeneca to acquire Icosavax in $1.1bn deal to boost vaccine development
In a definitive move, AstraZeneca has entered into an agreement to acquire Icosavax, Inc., a U.S.-based biopharmaceutical company specializing in innovative vaccines. This acquisition, valued at approximately $1.1 billion, signifies a major advancement in respiratory vaccine research, focusing on a novel protein virus-like particle (VLP) platform. The acquisition will significantly enhance AstraZeneca’s expertise in respiratory […]